{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:57:31Z","timestamp":1793757451004,"version":"4.6.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2025,9,7]]},"DOI":"10.1038\/s41416-025-03083-5","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T13:36:00Z","timestamp":1749735360000},"page":"464-472","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Genomic landscape of estrogen receptor-positive HER2-negative advanced breast cancer with acquired resistance to aromatase inhibitors: Identification of an ESR1 alteration-related gene signature"],"prefix":"10.1038","volume":"133","author":[{"given":"Solenn","family":"Barraud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0042-6023","authenticated-orcid":false,"given":"Sophie","family":"Vacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Schiffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6977-4213","authenticated-orcid":false,"given":"Abderaouf","family":"Hamza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Courtois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Pinton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Servant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3104-1684","authenticated-orcid":false,"given":"Sylvain","family":"Baulande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valery","family":"Attignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Soubeyran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Rouleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Coussy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Campone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Legrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4233-8478","authenticated-orcid":false,"given":"Marta","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5795-8357","authenticated-orcid":false,"given":"Fabrice","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0866-9484","authenticated-orcid":false,"given":"Thomas","family":"Bachelot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2430-5429","authenticated-orcid":false,"given":"Ivan","family":"Bi\u00e8che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"3083_CR1","unstructured":"SEER [Internet]. [cited 2024 Apr 11]. Female Breast Cancer Subtypes - Cancer Stat Facts. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/breast-subtypes.html."},{"key":"3083_CR2","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1056\/NEJMra1307118","volume":"383","author":"HJ Burstein","year":"2020","unstructured":"Burstein HJ. Systemic therapy for estrogen receptor-positive, HER2-negative breast cancer. N Engl J Med. 2020;383:2557\u201370.","journal-title":"N Engl J Med"},{"key":"3083_CR3","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375:1738\u201348.","journal-title":"N Engl J Med"},{"key":"3083_CR4","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS, Jones S, Im S-A, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925\u201336.","journal-title":"N Engl J Med"},{"key":"3083_CR5","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35:3638\u201346.","journal-title":"J Clin Oncol"},{"key":"3083_CR6","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrc3920","volume":"15","author":"CX Ma","year":"2015","unstructured":"Ma CX, Reinert T, Chmielewska I, Ellis MJ. Mechanisms of aromatase inhibitor resistance. Nat Rev Cancer. 2015;15:261\u201375.","journal-title":"Nat Rev Cancer"},{"key":"3083_CR7","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","volume":"34","author":"P Razavi","year":"2018","unstructured":"Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, et al. The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell. 2018;34:427\u201338.e6.","journal-title":"Cancer Cell"},{"key":"3083_CR8","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1152\/physrev.00026.2006","volume":"87","author":"N Heldring","year":"2007","unstructured":"Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev. 2007;87:905\u201331.","journal-title":"Physiol Rev"},{"key":"3083_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2004-5-9-r66","volume":"5","author":"CY Lin","year":"2004","unstructured":"Lin CY, Str\u00f6m A, Vega VB, Li Kong S, Li Yeo A, Thomsen JS, et al. Discovery of estrogen receptor \u03b1 target genes and response elements in breast tumor cells. Genome Biol. 2004;5:R66.","journal-title":"Genome Biol"},{"key":"3083_CR10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/bs.apcsb.2019.01.001","volume":"116","author":"N Fuentes","year":"2019","unstructured":"Fuentes N, Silveyra P. Estrogen receptor signaling mechanisms. Adv Protein Chem Struct Biol. 2019;116:135\u201370.","journal-title":"Adv Protein Chem Struct Biol"},{"key":"3083_CR11","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/nrc2211","volume":"7","author":"KA Green","year":"2007","unstructured":"Green KA, Carroll JS. Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state. Nat Rev Cancer. 2007;7:713\u201322.","journal-title":"Nat Rev Cancer"},{"key":"3083_CR12","first-page":"215","volume":"9","author":"SM Pejerrey","year":"2018","unstructured":"Pejerrey SM, Dustin D, Kim JA, Gu G, Rechoum Y, Fuqua SAW. The Impact of ESR1 mutations on the treatment of metastatic breast cancer. Horm. Cancer 2018;9:215\u201328.","journal-title":"Cancer"},{"key":"3083_CR13","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1158\/2159-8290.CD-15-1523","volume":"7","author":"W Toy","year":"2017","unstructured":"Toy W, Weir H, Razavi P, Lawson M, Goeppert AU, Mazzola AM, et al. Activating ESR1 mutations differentially affect the efficacy of ER antagonists. Cancer Discov. 2017;7:277\u201387.","journal-title":"Cancer Discov"},{"key":"3083_CR14","doi-asserted-by":"publisher","first-page":"4452","DOI":"10.1200\/JCO.2010.34.4879","volume":"29","author":"TW Miller","year":"2011","unstructured":"Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol J Am Soc Clin Oncol. 2011;29:4452\u201361.","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"3083_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/jnci\/95.5.353","volume":"95","author":"CK Osborne","year":"2003","unstructured":"Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SAW, et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2\/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003;95:353\u201361.","journal-title":"J Natl Cancer Inst"},{"key":"3083_CR16","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1172\/JCI41680","volume":"120","author":"TW Miller","year":"2010","unstructured":"Miller TW, Hennessy BT, Gonz\u00e1lez-Angulo AM, Fox EM, Mills GB, Chen H, et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest. 2010;120:2406\u201313.","journal-title":"J Clin Invest"},{"key":"3083_CR17","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1158\/0008-5472-CAN-04-3913","volume":"65","author":"LH Saal","year":"2005","unstructured":"Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 2005;65:2554\u20139.","journal-title":"Cancer Res"},{"key":"3083_CR18","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nature11143","volume":"486","author":"MJ Ellis","year":"2012","unstructured":"Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486:353\u201360.","journal-title":"Nature"},{"key":"3083_CR19","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl J Med. 2012;366:520\u20139.","journal-title":"N. Engl J Med"},{"key":"3083_CR20","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41416-023-02549-8","volume":"130","author":"H Vanacker","year":"2024","unstructured":"Vanacker H, Treilleux I, Schiffler C, Bieche I, Campone M, Patsouris A, et al. p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane. Br J Cancer. 2024;130:613\u20139.","journal-title":"Br J Cancer"},{"key":"3083_CR21","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41586-022-05068-3","volume":"610","author":"F Andre","year":"2022","unstructured":"Andre F, Filleron T, Kamal M, Mosele F, Arnedos M, Dalenc F, et al. Genomics to select treatment for patients with metastatic breast cancer. Nature. 2022;610:343\u20138.","journal-title":"Nature"},{"key":"3083_CR22","unstructured":"Oncokb\/oncokb-annotator [Internet]. OncoKBTM; 2024 [cited 2024 May 24]. Available from: https:\/\/github.com\/oncokb\/oncokb-annotator."},{"key":"3083_CR23","doi-asserted-by":"publisher","first-page":"D1210","DOI":"10.1093\/nar\/gkad986","volume":"52","author":"Z Sondka","year":"2024","unstructured":"Sondka Z, Dhir NB, Carvalho-Silva D, Jupe S, Madhumita, McLaren K, et al. COSMIC: a curated database of somatic variants and clinical data for cancer. Nucleic Acids Res. 2024;52:D1210\u20137.","journal-title":"Nucleic Acids Res"},{"key":"3083_CR24","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1158\/2159-8290.CD-17-0321","volume":"8","author":"MT Chang","year":"2018","unstructured":"Chang MT, Bhattarai TS, Schram AM, Bielski CM, Donoghue MTA, Jonsson P, et al. Accelerating discovery of functional mutant alleles in Cancer. Cancer Discov. 2018;8:174\u201383.","journal-title":"Cancer Discov"},{"key":"3083_CR25","doi-asserted-by":"crossref","unstructured":"Chakravarty D, Gao J, Phillips S, Kundra R, Zhang H, Wang J, et al. OncoKB: A Precision Oncology Knowledge Base. JCO Precision Oncology. 2017;1:1\u201316.","DOI":"10.1200\/PO.17.00011"},{"key":"3083_CR26","unstructured":"Dobin A alexdobin\/STAR [Internet]. 2024 [cited 2024 Jun 7]. Available from: https:\/\/github.com\/alexdobin\/STAR."},{"key":"3083_CR27","unstructured":"Suhrig. suhrig\/arriba [Internet]. 2024 [cited 2024 Mar 18]. Available from: https:\/\/github.com\/suhrig\/arriba."},{"key":"3083_CR28","unstructured":"Nicorici D ndaniel\/fusioncatcher [Internet]. 2024 [cited 2024 Mar 18]. Available from: https:\/\/github.com\/ndaniel\/fusioncatcher."},{"key":"3083_CR29","unstructured":"STAR-Fusion\/STAR-Fusion [Internet]. STAR-Fusion; 2024 [cited 2024 Mar 18]. Available from: https:\/\/github.com\/STAR-Fusion\/STAR-Fusion."},{"key":"3083_CR30","unstructured":"FusionInspector\/FusionInspector [Internet]. FusionInspector; 2024 [cited 2024 Jun 7]. Available from: https:\/\/github.com\/FusionInspector\/FusionInspector."},{"key":"3083_CR31","unstructured":"Clinical-Genomics\/fusion-report [Internet]. Clinical Genomics; 2024 [cited 2024 Jun 7]. Available from: https:\/\/github.com\/Clinical-Genomics\/fusion-report."},{"key":"3083_CR32","unstructured":"R: The R Project for Statistical Computing [Internet]. [cited 2024 Jun 7]. Available from: https:\/\/www.r-project.org\/."},{"key":"3083_CR33","unstructured":"Using clusterProfiler to characterize multiomics data | Nature Protocols [Internet]. [cited 2024 Oct 16]. Available from: https:\/\/www.nature.com\/articles\/s41596-024-01020-z."},{"key":"3083_CR34","unstructured":"Reactome Pathway Knowledgebase 2024 | Nucleic Acids Research | Oxford Academic [Internet]. [cited 2024 Jun 7]. Available from: https:\/\/academic.oup.com\/nar\/article\/52\/D1\/D672\/7369850?utm_source=advanceaccess&utm_campaign=nar&utm_medium=email."},{"key":"3083_CR35","doi-asserted-by":"publisher","first-page":"D587","DOI":"10.1093\/nar\/gkac963","volume":"51","author":"M Kanehisa","year":"2023","unstructured":"Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51:D587\u201392.","journal-title":"Nucleic Acids Res"},{"key":"3083_CR36","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1200\/JCO.2016.67.3061","volume":"34","author":"C Fribbens","year":"2016","unstructured":"Fribbens C, O\u2019Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M, et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J Clin Oncol J Am Soc Clin Oncol. 2016;34:2961\u20138.","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"3083_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35245-x","volume":"13","author":"S Sivakumar","year":"2022","unstructured":"Sivakumar S, Jin DX, Tukachinsky H, Murugesan K, McGregor K, Danziger N, et al. Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer. Nat Commun. 2022;13:7495.","journal-title":"Nat Commun"},{"key":"3083_CR38","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1093\/annonc\/mdy025","volume":"29","author":"RJ Hartmaier","year":"2018","unstructured":"Hartmaier RJ, Trabucco SE, Priedigkeit N, Chung JH, Parachoniak CA, Vanden Borre P, et al. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer. Ann Oncol. 2018;29:872\u201380.","journal-title":"Ann Oncol"},{"key":"3083_CR39","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1096\/fj.13-247353","volume":"28","author":"KL Cook","year":"2014","unstructured":"Cook KL, Clarke PAG, Parmar J, Hu R, Schwartz-Roberts JL, Abu-Asab M, et al. Knockdown of estrogen receptor-\u03b1 induces autophagy and inhibits antiestrogen-mediated unfolded protein response activation, promoting ROS-induced breast cancer cell death. FASEB J. 2014;28:3891\u2013905.","journal-title":"FASEB J"},{"key":"3083_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-56412-8","volume":"14","author":"T De Marchi","year":"2024","unstructured":"De Marchi T, Lai CF, Simmons GM, Goldsbrough I, Harrod A, Lam T, et al. Proteomic profiling reveals that ESR1 mutations enhance cyclin-dependent kinase signaling. Sci Rep. 2024;14:6873.","journal-title":"Sci Rep"},{"key":"3083_CR41","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41588-018-0287-5","volume":"51","author":"U Nayar","year":"2019","unstructured":"Nayar U, Cohen O, Kapstad C, Cuoco MS, Waks AG, Wander SA, et al. Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor\u2013directed therapies. Nat Genet. 2019;51:207\u201316.","journal-title":"Nat Genet"},{"key":"3083_CR42","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1158\/1078-0432.CCR-18-1544","volume":"25","author":"S Croessmann","year":"2019","unstructured":"Croessmann S, Formisano L, Kinch LN, Gonzalez-Ericsson PI, Sudhan DR, Nagy RJ, et al. Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+\/HER2 Mutant Breast Cancer. Clin Cancer Res J Am Assoc Cancer Res. 2019;25:277\u201389.","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"3083_CR43","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.annonc.2023.08.003","volume":"34","author":"K Jhaveri","year":"2023","unstructured":"Jhaveri K, Eli LD, Wildiers H, Hurvitz SA, Guerrero-Zotano A, Unni N, et al. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial. Ann Oncol J Eur Soc Med Oncol. 2023;34:885\u201398.","journal-title":"Ann Oncol J Eur Soc Med Oncol"},{"key":"3083_CR44","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1158\/1078-0432.CCR-18-4044","volume":"26","author":"A Pearson","year":"2020","unstructured":"Pearson A, Proszek P, Pascual J, Fribbens C, Shamsher MK, Kingston B, et al. Inactivating NF1 mutations are enriched in advanced breast cancer and contribute to endocrine therapy resistance. Clin Cancer Res. 2020;26:608\u201322.","journal-title":"Clin Cancer Res"},{"key":"3083_CR45","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1158\/0008-5472.CAN-17-1327","volume":"78","author":"Y Wu","year":"2018","unstructured":"Wu Y, Zhang Z, Cenciarini ME, Proietti CJ, Amasino M, Hong T, et al. Tamoxifen resistance in breast cancer is regulated by the EZH2-ER\u03b1-GREB1 Transcriptional Axis. Cancer Res. 2018;78:671\u201384.","journal-title":"Cancer Res"},{"key":"3083_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14098-x","volume":"11","author":"J Achinger-Kawecka","year":"2020","unstructured":"Achinger-Kawecka J, Valdes-Mora F, Luu PL, Giles KA, Caldon CE, Qu W, et al. Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer. Nat Commun. 2020;11:320.","journal-title":"Nat Commun"},{"key":"3083_CR47","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1126\/science.283.5407.1488","volume":"283","author":"M Saraste","year":"1999","unstructured":"Saraste M. Oxidative Phosphorylation at the fin de si\u00e8cle. Science. 1999;283:1488\u201393.","journal-title":"Science"},{"key":"3083_CR48","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden MG, Cantley LC, Thompson CB. Understanding the warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029\u201333.","journal-title":"Science"},{"key":"3083_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40022-5","volume":"14","author":"R El-Botty","year":"2023","unstructured":"El-Botty R, Morriset L, Montaudon E, Tariq Z, Schnitzler A, Bacci M, et al. Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers. Nat Commun. 2023;14:4221.","journal-title":"Nat Commun"},{"key":"3083_CR50","doi-asserted-by":"publisher","first-page":"4954","DOI":"10.3390\/ijms24054954","volume":"24","author":"L Zhang","year":"2023","unstructured":"Zhang L, Wei Y, Yuan S, Sun L. Targeting mitochondrial metabolic reprogramming as a potential approach for cancer therapy. Int J Mol Sci. 2023;24:4954.","journal-title":"Int J Mol Sci"},{"key":"3083_CR51","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41591-022-02103-8","volume":"29","author":"TA Yap","year":"2023","unstructured":"Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, et al. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med. 2023;29:115\u201326.","journal-title":"Nat Med"},{"key":"3083_CR52","doi-asserted-by":"publisher","first-page":"102784","DOI":"10.1016\/j.ebiom.2020.102784","volume":"56","author":"SL Stenton","year":"2020","unstructured":"Stenton SL, Prokisch H. Genetics of mitochondrial diseases: Identifying mutations to help diagnosis. eBioMedicine. 2020;56:102784.","journal-title":"eBioMedicine"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03083-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03083-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03083-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T19:22:54Z","timestamp":1757186574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03083-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,9,7]]}},"alternative-id":["3083"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03083-5","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"assertion":[{"value":"3 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}